Position on Early Access and Post-Trial Access to Investigational Therapy

Background

Our Position

Additional Information

Our guiding principles

The Access to Medicines philosophy at Astellas is guided by the principles of international ethical frameworks such as the Declaration of Helsinki, ICH Good Clinical Practices and other relevant international guidelines.3,4 Astellas has controlled procedures in place to support prompt and fair decision-making, while ensuring a consistent approach for managing these programs throughout the world in compliance with applicable laws and regulations.

 

Access to cell and gene therapy

The access mechanisms implemented by Astellas are multifaceted, require close evaluation, and may be shaped by country specific regulations. This is especially true for more complex treatment forms such as cell and gene therapies where clinical and regulatory requirements vary and are rapidly evolving.

 

Additionally, cell and gene therapies typically require administration by highly trained physicians who have access to the diagnostics, equipment and resources needed to ensure the highest level of safety possible. For this reason, Astellas will continue to focus on bringing safe and effective cell and gene therapies to market as quickly as possible, with the quality controls required to develop these innovative therapies.

References